Previous 10 | Next 10 |
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. Investors using the Robinhood platform are known for seeking out stocks that may make big share moves in a short period. As a long-term investor, I'm more interested in stocks that will steadily climb...
Are These The Best Biotech Stocks To Add To Your List Before December? Going into December, the top biotech stocks continue to flourish. It has undoubtedly been the year for biotech companies in the stock market as they are essentially the frontline industry in the fight aga...
SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation is made av...
Defense Advanced Research Projects Agency ((DARPA)) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) awarded SmartPharm Therapeutics, wholly-owned subsidiary of Sorrento Therapeutics (SRNE) +17% PM, a contract fo...
Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAb TM through Phase 2 clinical studies. ST...
In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , highlights what investors should expect from the biotech's COVID-19 products in months ahead. Ji also talks about the company's financial sit...
Sorrento Therapeutics (NASDAQ: SRNE) arguably has the most diverse set of products for the COVID-19 pandemic. In this video from Motley Fool Live recorded on Nov. 12, executives from the company talk about a few of the biotech's preclinical products. Salicyn 30 is an an...
Sorrento Therapeutics (NASDAQ: SRNE) has taken a broad approach to developing tests, treatments, and vaccines for COVID-19. In the process, the biotech certainly hasn't broken any biotech speed records and trails the leaders in each of the three categories. Nevertheless, in this...
Sorrento Therapeutics (NASDAQ: SRNE) is considerably behind Pfizer (NYSE: PFE) , BioNTech (NASDAQ: BNTX) , Moderna (NASDAQ: MRNA) , and the rest of the leaders in the race to develop a coronavirus vaccine. While multiple vaccines have completed phase 3 clinic...
In this video from Motley Fool Live recorded on Nov. 12, executives from Sorrento Therapeutics (NASDAQ: SRNE) talk about the company's second-generation therapeutic antibody. An investigational new drug (IND) application has been submitted to the Food and Drug Administration. ...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
What goes up usually comes down, and that's exactly what happened with Sorrento Therapeutics (NASDAQ: SRNE) today. Shares of Sorrento were crashing 30.4% as of 3:38 p.m. ET on Wednesday after soaring more than 60% on Tuesday. Sorrento's huge surge yesterday came after the company anno...
A California-based %Biotech company is turning heads Wednesday morning after it was announced that the U.S. Bankruptcy Court granted an interim approval of the company’s $75 million debtor-in-possession financing. While bankruptcy court can get a little messy, traders seem to b...